日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Incidence and oncologic outcomes of patients with prostate-specific antigen persistence after radical prostatectomy

根治性前列腺切除术后前列腺特异性抗原持续存在的患者的发生率和肿瘤学预后

Lane, Brian R; Lewicki, Patrick; Noyes, Sabrina L; Labardee, Corinne; Meah, Sabir; Daignault-Newton, Stephanie; Hafron, Jason; Morgan, Todd M; Radhakrishnan, Archana; Dess, Robert T; Montie, James; Ghani, Khurshid R; Ginsburg, Kevin B; Borza, Tudor

Impact of a rash management guide in patients receiving apalutamide for high-risk localized prostate cancer in the Apa-RP study

在 Apa-RP 研究中,接受阿帕鲁胺治疗的高危局限性前列腺癌患者皮疹管理指南的影响

Shore, Neal; Hafron, Jason; Saltzstein, Daniel; Bhaumik, Amitabha; Aggarwal, Pankaj; Phillips, Jennifer; McGowan, Tracy

Active surveillance selection and 3-year durability in intermediate-risk prostate cancer following genomic testing

基因组检测后,中危前列腺癌患者的主动监测选择及3年疗效持久性

Lenz, Lauren; Clegg, Wyatt; Iliev, Diana; Kasten, Chelsea R; Korman, Howard; Morgan, Todd M; Hafron, Jason; DeHaan, Alexander; Olsson, Carl; Tutrone, Ronald F Jr; Richardson, Timothy; Cline, Kevin; Yonover, Paul M; Jasper, Jeff; Cohen, Todd; Finch, Robert; Slavin, Thomas P Jr; Gutin, Alexander

Study of persistence and adherence to ADT in prostate cancer: relugolix, degarelix, and GnRH agonists in the US

美国前列腺癌ADT治疗的持续性和依从性研究:瑞卢戈利、地加瑞克和GnRH激动剂

Hafron, Jason; Hong, Agnes; Ryan, Michael J; Romdhani, Hela; Kinkead, Frédéric; Flanders, Scott C; McKay, Rana R

Cellular Immunotherapy for Prostate Cancer: Lessons Learned From 15 Years of Sipuleucel-T

前列腺癌细胞免疫疗法:Sipuleucel-T 15 年的经验教训

Shore, Neal D; Antonarakis, Emmanuel S; Hafron, Jason; Moses, Kelvin A; Pieczonka, Christopher; Lowentritt, Benjamin; Sheikh, Nadeem; George, Daniel J; Dorff, Tanya Barauskas

Detection of Germline Variants in Patients With Localized and Metastatic Prostate Cancer Through Guideline-Based Testing

通过基于指南的检测方法检测局限性和转移性前列腺癌患者的种系变异

Abusamra, Sophia M; Solorzano, Marissa A; Quarles, Jake; Luke, Mallory; Patel, Milan; Vince, Randy Jr; Jiang, Ralph; Volin, Joshua; Jacobs, Michelle F; Kaffenberger, Samuel D; Salami, Simpa S; Palmbos, Phillip; Caram, Megan E V; Hollenbeck, Brent K; Palapattu, Ganesh S; Merajver, Sofia D; Stoffel, Elena M; Hafron, Jason; Morgan, Todd M; Reichert, Zachery R

Cardiovascular Risk in Prostate Cancer Patients Using Luteinizing Hormone-Releasing Hormone Agonists or a Gonadotropin-Releasing Hormone Antagonist

使用促黄体生成素释放激素激动剂或促性腺激素释放激素拮抗剂治疗前列腺癌患者的心血管风险

Crawford, E David; Hafron, Jason M; Debruyne, Frans; Wallis, Christopher; Chang, Steven; Garnick, Marc B

Development and Optimization of a Subtraction-Normalized Immunocyte Profiling Signature for Prostate Cancer Active Surveillance Risk Stratification

前列腺癌主动监测风险分层中减法归一化免疫细胞谱特征的开发与优化

Van Neste, Leander; Henao, Ricardo; Wojno, Kirk J; Signes, Jorge; DeHart, Jessica; Busta, Angela; Marriott, Elyse; Willing, Marian; Argentini, Andrea; Hurley, Patrick M; Korman, Howard; Hafron, Jason; Putzi, Mathew; Pieczonka, Chris M; Karsh, Lawrence I; Morris, David S; Kassis, Amin I; Kantoff, Philip W

Apalutamide for High-Risk Localized Prostate Cancer Following Radical Prostatectomy (Apa-RP)

阿帕鲁胺治疗根治性前列腺切除术后高危局限性前列腺癌(Apa-RP)

Shore, Neal; Hafron, Jason; Saltzstein, Daniel; Brown, Gordon; Belkoff, Laurence; Aggarwal, Pankaj; Phillips, Jennifer; Bhaumik, Amitabha; McGowan, Tracy

Enhancing Therapeutic Efficacy and Safety of Immune Checkpoint Inhibition for Bladder Cancer: A Comparative Analysis of Injectable vs. Intravesical Administration

提高膀胱癌免疫检查点抑制剂的治疗效果和安全性:注射给药与膀胱内给药的比较分析

Tyagi, Pradeep; Hafron, Jason; Kaufman, Jonathan; Chancellor, Michael